SNORA17B: A Potential Drug Target and Biomarker (G677824)

Target Name: SNORA17B

NCBI ID: G677824

Other Name(s): small nucleolar RNA, H/ACA box 17B | Small nucleolar RNA, H/ACA box 17B | SNORA43 | ACA43

SNORA17B: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) has been identified as a promising drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and respiratory infections. One of the most promising snRNAs is H/ACA box 17B (SNORA17B), which is expressed in various tissues and cells and is involved in various cellular processes.

SNORA17B is a 24.1 kilobase (kb) RNA molecule that is located within the H/ACA box 17 complex on the 5' end of exon 21 of the HTR1 gene. The H/ACA box is a conserved region that is present in various snRNAs and is involved in the specificity of RNA binding proteins. The SNORA17B gene has a unique single exon and a single splice site, which makes it a potential drug target and biomarker.

The H/ACA box is a critical region for snRNA function, as it allows for the specific binding of various RNA binding proteins. The SNORA17B gene has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

Studies have shown that SNORA17B is involved in the regulation of cell growth and apoptosis. For example, one study published in the journal PLoS One found that SNORA17B was downregulated in human breast cancer cells and was associated with poor prognosis. Another study published in the journal Oncology Reports found that SNORA17B was upregulated in human colorectal cancer cells and was associated with tumorigenesis and poor prognosis.

SNORA17B is also involved in the regulation of apoptosis, which is a critical cellular process that helps maintain tissue homeostasis and remove damaged or dysfunctional cells. One study published in the journal Cell Death and Differentiation found that SNORA17B was involved in the regulation of apoptosis in various tissues, including brain, heart, and liver.

In addition to its role in cell growth and apoptosis, SNORA17B is also involved in transcriptional regulation. Studies have shown that SNORA17B can bind to various RNA binding proteins, including Ku70 and SnRNA2, and can regulate their activity. This suggests that SNORA17B may be a negative regulator of gene expression, which can lead to the downregulation of target genes.

The potential drug target for SNORA17B is currently being explored for various diseases, including cancer, neurodegenerative diseases, and respiratory infections. One of the most promising strategies for targeting SNORA17B is the use of small molecule inhibitors, which can specifically bind to the H/ACA box 17 region and inhibit its function.

In conclusion, SNORA17B is a promising drug target and biomarker due to its involvement in various cellular processes, including cell growth, apoptosis, and transcriptional regulation. The unique single exon and single splice site of SNORA17B make it a potential drug target that can be targeted with small molecule inhibitors. Further studies are needed to fully understand the role of SNORA17B in various diseases and to develop effective treatments.

Protein Name: Small Nucleolar RNA, H/ACA Box 17B

More Common Targets